azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin Lymphoma (NHL)
Conditions
Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Acute Myeloid Leukemia (AML)
Trial Timeline
Sep 22, 2014 → Mar 12, 2021
NCT ID
NCT02265731About azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8
azacitadine + venetoclax + rituximab / IDEC-C2B8 + rituximab / IDEC-C2B8 is a phase 1/2 stage product being developed by AbbVie for Non-Hodgkin Lymphoma (NHL). The current trial status is completed. This product is registered under clinical trial identifier NCT02265731. Target conditions include Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL).
What happened to similar drugs?
8 of 20 similar drugs in Non-Hodgkin Lymphoma (NHL) were approved
Approved (8) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02265731 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-Hodgkin Lymphoma (NHL)